These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31284931)

  • 21. Drug Development and Biologics in Asthma. A New Era.
    Doyle R
    Ann Am Thorac Soc; 2016 Mar; 13 Suppl 1():S83-4. PubMed ID: 27027958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of asthma endotypes: implications for therapy.
    Stokes JR; Casale TB
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M; Dyer Z
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract]   [Full Text] [Related]  

  • 25. [Role of monoclonal anti-IgE antibodies (rhu-MAb) in the treatment of allergic bronchial asthma].
    Targowski T; From S
    Pol Merkur Lekarski; 2003 Jan; 14(79):65-8. PubMed ID: 12712834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
    Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Asthma therapy in transition. "For the physician it becomes ever more complicated" (interview by Dr. Elke Oberhofer)].
    Gillissen A; Oberhofer E
    MMW Fortschr Med; 2014 Jun; 156(11):31. PubMed ID: 25022087
    [No Abstract]   [Full Text] [Related]  

  • 28. Unconventional treatment options in severe asthma: an overivew.
    Banh HL
    J Pharm Pharm Sci; 2011; 14(3):387-99. PubMed ID: 22202222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological treatments for severe asthma: where do we stand?
    Busse WW
    Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Biologics in Asthma Treatment.
    Imanirad D; Tabatabaian F
    Semin Respir Crit Care Med; 2022 Oct; 43(5):627-634. PubMed ID: 36220056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eosinophilic and Noneosinophilic Asthma.
    Carr TF; Zeki AA; Kraft M
    Am J Respir Crit Care Med; 2018 Jan; 197(1):22-37. PubMed ID: 28910134
    [No Abstract]   [Full Text] [Related]  

  • 33. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.
    Caruso M; Crisafulli E; Demma S; Holgate S; Polosa R
    Expert Opin Biol Ther; 2013 Mar; 13(3):393-402. PubMed ID: 23289846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?
    Koenderman L; Hassani M; Mukherjee M; Nair P
    Allergy; 2021 Apr; 76(4):1294-1297. PubMed ID: 33301608
    [No Abstract]   [Full Text] [Related]  

  • 36. Prospects for severe asthma treatment.
    Calzetta L; Matera MG; Coppola A; Rogliani P
    Curr Opin Pharmacol; 2021 Feb; 56():52-60. PubMed ID: 33310456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asthma biologics: Underuse, overuse, and best use?
    Rank MA; Oppenheimer JJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):358-359. PubMed ID: 30578858
    [No Abstract]   [Full Text] [Related]  

  • 38. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model.
    Deurloo DT; van Esch BC; Hofstra CL; Nijkamp FP; van Oosterhout AJ
    Am J Respir Cell Mol Biol; 2001 Dec; 25(6):751-60. PubMed ID: 11726402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
    Pepper AN; Hanania NA; Humbert M; Casale TB
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.